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ABSTRACT 
Background: An aberrant right hepatic artery (ARHA) is a common anatomical variation. 
The risk associated with ARHA during pancreaticoduodenectomy (PD) continues to be 
debated. The aim of this study was to compare the clinical outcomes and survival after PD 
with ARHA against a matched cohort of patients without AHRA. 
 
Methods: PD with an ARHA performed between January 2000 and September 2009 were 
retrospectively analyzed. Patients with an AHRA (group 1) were matched (1:2) to patients 
without an ARHA (group 2) according to gender, age, BMI, type of tumor and lymph nodes 
status. Peri- and postoperative outcomes were compared between the 2 groups. Overall 
(OS) and disease free (DFS) survival were estimated by Kaplan-Meier method and 
compared with Log-rank test.  
 
Results: A total of 29 patients (group 1) and 55 patients (group 2) were compared. In group 
1, an AHRA entered the tumor in 6 cases (20.7%), was sacrificed in 4 cases, and repaired in 
2 cases. There was no difference regarding the rate of intraoperative and postoperative 
variables between the 2 groups. The oncological clearance (p=0.731) and survival (OS, 
p=0.843; DFS, p=0.832) were also similar. 
 
Conclusions: Our study showed that the presence of an AHRA during PD was not 
associated with worse postoperative outcomes or survival.
INTRODUCTION 
Pancreaticoduodenectomy (PD) remains the only curative treatment currently available for 
malignant diseases of the pancreatic head. Improvements in operative techniques and 
postoperative care have significantly decreased the mortality after PD within the last two 
decades in high-volume centers (1;2). The morbidity rates after PD remain high, reaching 
30-50% (3;4). Morbidity is partly related to peri- and postoperative hemorrhage (5;6), which 
may be due to the highly variable arterial anatomy, particularly the anatomy of the hepatic 
artery (HA). These variations were fully described by Michels (7) from 200 autopsies and 
confirmed by Hiats et al. on 1000 liver donors (8). Among these anatomical variations, the 
Achilles heel during PD is the presence of an aberrant right hepatic artery (ARHA), including 
a replaced and accessory right hepatic artery, which is present in 10 to 18% of the 
population (8;9). ARHAs arise from the superior mesenteric artery (SMA), cross behind or 
through the head of the pancreas before skirting laterally or behind the portal vein, and 
finally penetrate the hepaticoduodenal ligament postero-laterally to the bile duct. It is 
imperative to look for the presence of an ARHA pre- and perioperatively to avoid its injury. 
When an AHRA is present, the challenge in peripancreatic malignant disease is the balance 
between its preservation and the need to achieve oncological clearance, which represents 
the only chance for prolonged survival. To date, few studies have evaluated the impact of 
the presence of an ARHA during PD in this difficult situation (10-13). These studies focused 
more on the management of ARHAs than on the impact that ARHAs have on recurrence and 
survival. 
The aim of this study was to retrospectively analyze the outcomes and oncological results of 
PD in patients with ARHA when performed in a tertiary referral center. Particular attention 
was focused on the risk of an incomplete resection associated with the presence of ARHA.  
METHODS 
Patients 
The study population included all of the consecutive PD for malignant disease that were 
performed at a single tertiary referral center between January 2000 and September 2009. 
The clinical data were retrospectively analyzed after retrieval from a prospectively collected 
PD database. Institutional Review Board approval was obtained for this study. 
The collected data included age, sex, body mass index (BMI), tumor type, lymph node 
status, duration of surgery, venous or arterial resection and reconstruction, concomitant 
abdominal surgery, and transfusion needs. The postoperative complications of pancreatic 
fistula rates, classified into three groups (A, B, and C) according to the International Study 
Group of Pancreatic Fistula (ISGPF) criteria(14), and delayed gastric emptying (DGE) 
graded according to International Study Group of Pancreatic Surgery (ISPGS) criteria (15) 
were assessed. In this series, only pancreatic fistulas of grades B and C were considered 
because the nasogastric tube (NGT) was systematically left in place for 5 days. We also 
assessed postpancreatectomy hemorrhage, including intra- and extra-luminal bleeding 
according to the ISGPS definition; biliary fistula, defined as the presence of bile in the 
drainage fluid; and systemic infections, defined as the association of infectious signs with the 
need for systemic antibiotics. Perioperative mortality was defined as death during the initial 
hospital stay or within 30 days of surgery if the patient was discharged. 
Surgery and Follow-up protocol 
All patients underwent PD with an antrectomy and Child reconstruction. All of the procedures 
were performed by senior pancreatic surgeons, and a superior mesenteric artery first 
approach was performed systematically after 2006.  In the last years of the study period, the 
decision to sacrifice or repair was based on the caliber of the artery, the presence or 
absence of a back flow from the distal part of the artery and the results of intraoperative liver 
Doppler ultrasonography. Adjuvant chemotherapy was systematically administrated for 
patient with pancreatic adenocarcinoma with gemcitabine, whereas patients with distal bile 
duct cholangiocarninoma had not. Regarding malignant ampulloma, only patients with 
positive lymph nodes involvement benefited from chemotherapy by FOLFOX or LV5FU2 
regiments. After the resection, all patients were followed up every three months. A CT scan 
was performed every 3 months during the first 2 years and every six months thereafter.  
Follow-up data were obtained through routine clinic visits or through personal contact. The 
end of follow-up was set at August 1, 2012, or at the time of death.  
Statistical analysis 
To analyze the impact of the presence of ARHA during PD, the patients with an ARHA were 
identified by reviewing surgical reports (group 1) and were matched one-to-two with patients 
without an ARHA (group 2) from the PD database. The match was obtained according to 
age, sex, BMI, tumor type and lymph node status. 
The quantitative variables were expressed as the mean ± standard deviation (SD) or the 
median value and compared using Student’s t-test or Wilcoxon test as appropriate. The 
qualitative variables were expressed as the mean ± SD and percentage and compared by 
Chi-squared or Fisher’s exact tests, as appropriate. The cumulative survival rates were 
estimated by the Kaplan-Meier method. The overall survival (OS) was calculated from the 
day of surgery to the date of death or the end of follow-up. Disease-free survival (DFS) was 
calculated using the date of death or recurrence as the time of the terminal event. The 
survival curves were compared by a log-rank test. A p value of < 0.05 was considered 
statistically significant. R statistical software, version 2.15.1 (http://www.r-project.org/), was 
used. 
RESULTS 
Demographic data and matched group 
During the study period, 213 patients underwent PD with curative intent for malignant 
disease. Among these 213 patients, 29 (13.6%) had an ARHA (group 1), including 18 (62%) 
cases and 11 (38%) cases of type 6 (accessory RHA) and type 3 (replaced RHA) of the 
Michels classification, respectively They were matched 1:2, and only 55 patients (group 2) of 
the 58 planned matches were found according to the matching criteria. The demographic 
data and histopathology features of the two groups are reported in table 1 and show great 
matching correlation. 
In group 1, AHRAs were diagnosed preoperatively by CT scan or angio-MRI (Figure 1A and 
1B) or during surgery in 20 (69%) and 9 (31%) cases, respectively. No patient received 
preoperative embolization of the ARHA to prevent any possible complications related to 
intraoperative sacrifice. Among the 29 cases of ARHA, 23 (79.3%) were dissected free and 
preserved (figure 1C), whereas 6 crossed into the tumor (20.7%) and were either sacrificed 
in 4 cases or reconstructed in 2 cases (figure 2).  
 
Perioperative data and outcomes 
Peri- and postoperative outcomes of the two groups are provided in table 2. There were no 
significant differences between the 2 groups in terms of the surgical parameters, the 
postoperative outcome, or the extent of resection. No cases of liver failure, infarction, 
abscess or biliary fistula were found in group 1. The extent of resection and the histological 
feature of the 2 groups are provided in table 3 and show that the R0 rates were similar in the 
2 groups (p=0.731) 
Long-term survival 
The mean global follow-up was 36 ± 36 months. The OS and DFS of the entire studied 
population are shown in figures 3A and 3B, respectively. The overall median survival time 
was 21.8 months in group 1 and 23.6 months in group 2, without significant intergroup 
differences (p=0.843). The median DFS was 11.2 in group 1 and 13.3 months in group 2 
(p=0.832).
DISCUSSION 
While several studies have examined the prognostic value of clinical and histological factors, 
including age, BMI, lymph node invasion, and margin thickness, few have evaluated the 
impact of anatomical variations, such as the presence of ARHA on the postoperative course 
of PD(10-13). This matched case-controlled study showed that the presence of an ARHA did 
not impact the perioperative complications or the oncological prognosis.  
Although special attention was paid to determine the presence of an ARHA during 
preoperative explorations, a high percentage of ARHA was ignored until surgery.  Indeed, 
about one-third of ARHAs were discovered perioperatively, a feature that has been 
described previously (12). Stauffer et al. reported a rate of preoperatively unknown ARHA of 
64%(11). This finding emphasizes the need for standardization of imaging reports that 
mention the presence or absence of arterial anatomical variations prior to PD. This 
knowledge may allow for preoperative embolization to avoid perioperative hemorrhagic 
complications. Preoperative embolization favors the development of arterial collaterals to the 
liver, including the opening of intrahepatic shunts, which may prevent the risk of liver failure 
when an ARHA must be sacrificed (16). We never opted for this procedure which probably 
doesn’t decrease the risk of biliary anastomotic fistula. When an ARHA appears to be 
invaded preoperatively, neoadjuvant chemo-radiotherapy may be indicated to reduce the 
rate of incomplete resection with arterial preservation (12). To bridge the lack of relevance of 
imaging results, we suggest that all PD begin through a SMA right first approach with 
dissection to free the first 3 centimeters, where AHRAs mostly arise (17;18). From an 
oncological point of view, the SMA first approach (a right-to-left early retropancreatic 
dissection) may reduce the rate of an R1 or R2 resection.  
This study also provided information regarding the management of ARHAs in patients with 
cancer of the pancreatic head. Although one-fifth of AHRAs crossed through the tumor, the 
vessel could be preserved in most cases, an observation that is in line with previous reports 
(13;19) and which could explain the lack of significant differences between the 2 groups in 
our study.  
In our series, 4 small caliber ARHA were sacrificed without relevant postoperative 
consequences. Unfortunately, we have little information about the decision to sacrifice or 
reconstruct the ARHA, especially concerning the back-flow from the distal part in the cases 
where arteries were sacrificed.  To date, no report about the cut-off caliber from which ARHA 
might be repaired has been published. When the main hepatic artery arises from the SMA 
(type 9 of Michel’s classification), it must be repaired (17). We learned from liver 
transplantation techniques that when an ARHA reconstruction is necessary, the easiest way 
to do so is to bridge the ARHA in the stump of the gastro-duodenal artery (GDA). After PD, 
the GDA stump is frequently not usable, and the ARHA can be reimplanted in the splenic 
artery end-to-end or end-to-side using a saphenous vein jump graft. 
One bias in our study is that all PD were performed by senior surgeons with a large amount 
of experience in liver transplantation and a routine level of experience in arterial hepatic 
dissection and reconstruction, which may have reduced the postoperative morbidity and the 
incidence of R1 or R2 resections. Performing intraoperative liver Doppler ultrasonography is 
recommended to ensure the results of the arterial sacrifice or reconstruction and to prevent 
postoperative complications (20;21). We believe that surgical expertise is a key point in 
pancreatic surgery to reduce morbidity and improve survival, and these patients should be 
managed in high-volume centers (1;2;22). 
In conclusion, this matched case-controlled study showed that the presence of an AHRA 
during PD for malignant disease was not associated with an increased rate of postoperative 
complications or reduced OS or DFS. Patients requiring PD should be referred to upper GI 
surgical centers where digestive arterial reconstructions are routinely performed. This 
improves the safety of complex pancreatic surgery without jeopardizing the oncological 
prognosis. 
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Figure 1. Type-3 ARHA by Michels classification (replaced RHA). 1A. Enhanced axial 
CT-scan showing an AHRA (white arrow). 1B. Enhanced angio-MRI showing AHRA 
(white arrow). 1C. Intraoperative picture showing a preserved type-3 AHRA (white 
arrow) and SMA (black arrow). 
 
Figure 2. Diagram chart 
 
Figure 3. Survival according to the presence (group 1) or absence (group 2) of an 
ARHA. 3A Overall survival, log-rank test, P=0.843; 3B Disease-free survival, log-rank 
test, P=0.832 
Table 1. Demographic data and histopathological features of the two matching groups 
 
Variable 
Group 1 
AHRA 
 
Group 2      
no AHRA 
p 
 n (%)  n (%)  
Number 29  55  
Sex    0.861 
          male 16 (55)  30 (55)  
          female 13 (45)  25 (45)  
Age (years)* 62.9±12  62.5±11 0.861 
Body mass index* 24.5±4  24.4±4 0.921 
Type of tumor    0.975 
   pancreatic adenocarcinoma 19  38  
   malignant ampulloma 3  6  
   cholangiocarcinoma 5  7  
   endocrine tumor 2  4  
Lymph node status (N+) 16 (55)  26 (47) 0.646 
 
 
Table 2. Surgical data and postoperative complications according to the presence of 
an ARHA 
 
Variable 
Group 1 
AHRA 
 
Group 2      
no AHRA 
p 
 n (%)  n (%)  
Number 29  55  
 
Surgical procedure parameters 
    
     operative time (min)* 334.5±83  341±106 0.984 
     vein resection 4 (14)  16 (29) 0.195 
     adjacent organ resection 3 (10)  4 (7) 0.688 
     pancreatic duct stenting 15 (51)  30 (55) 0.987 
     intraoperative blood infusion 18 (62)  29 (53) 0.556 
     
Postoperative parameters     
     length of hospital stay (days)* 17.2±8  20.7±13 0.314 
     delayed gastric emptying 10 (34)  24 (44) 0.562 
                    grade B 5 (17)  13 (24)  
                    grade C 5 (17)  11 (20)  
     pancreatic fistula 3 (10)  9 (16) 0.531 
                    grade A 0 (0)  0 (0)  
                    grade B 2 (7)  5 (9)  
                    grade C 1 (3)  4 (7)  
     postoperative hemorrhage 4 (14)  9 (16) 1 
     biliary fistula 0 (0)  2 (4) 0.542 
     systemic infection 7 (24)  21 (38) 0.292 
     surgical revision 8 (28)  10 (18) 0.913 
     morbidity 14 (48)  32 (58) 0.524 
     postoperative mortality 3 (10)  3 (5) 0.411 
     
     
     
     
     
     
     
 
 
Table 3: Extent of resection and histological features after resection in patients with 
or without ARHAs 
 
Variable 
Group 1 
AHRA 
 
Group 2      
no AHRA 
p 
 n (%)  n (%)  
Number 29  55  
     
R0 resection 25 (86)  49 (89) 0.731 
lymph Nodes status (N+) 16 (55)  26 (47) 0.646 
vascular embolization 8 (28)  10 (18) 0.472 
perineural infiltration 13 (45)  25 (45) 0.861 
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Figure 1. Type-3 ARHA by Michels classification (replaced RHA). 1A. Enhanced axial 
CT-scan showing an AHRA (white arrow). 1B. Enhanced angio-MRI showing an AHRA 
(white arrow). 1C. Intraoperative picture showing a preserved type-3 AHRA (white 
arrow) and SMA (black arrow). 
 
Figure 2. Diagram chart  
Pancreaticoduodenectomy for 
malignant disease 
n=213 
 
Group 1 
AHRA, n=29 
Group 2 
n=55 
n=14 
AHRA preserved 
n=23 
AHRA reconstructed 
n=2 
AHRA sacrificed 
n=4 
Matching criteria 
Age, Sex, BMI, Type of 
tumor, Lymph node status 
Figure 3A. 
 
 
Overall survival according to the presence (group 1) or absence (group 2) of ARHAs. 
Log-rank test, P=0.843
Figure 3B. 
 
 
 
Disease-free survival according to the presence (group 1) or absence (group 2) of 
ARHAs. Log-rank test, P=0.832 
